<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Int AIDS Soc</span><span class="iso-abbrev" title="iso-abbrev">J Int AIDS Soc</span><span class="doi" title="doi">10.1002/(ISSN)1758-2652</span><span class="publisher-id" title="publisher-id">JIA2</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of the International AIDS Society</span></div><span class="issn-epub" tagx="issn" title="issn-epub">1758-2652</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">John Wiley and Sons Inc.</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Hoboken</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7507004">7507004</a></span><span class="pmid" title="pmid"> pmid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/32949103">32949103</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1002/jia2.25610">10.1002/jia2.25610</a></span><span class="publisher-id" title="publisher-id">JIA225610</span><div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Research Article</span>: <span class="subject" title="subject">Research Articles</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Early access to antiretroviral therapy versus standard of care among HIVâ€�positive participants in Eswatini in the public health sector: the MaxART steppedâ€�wedge randomized controlled trial</div> <div class="alt-title" title="alt-title">
Khan S et al.</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">Shaukat</span></span><a href="#jia225610-aff-0001"><sup>1</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Spiegelman</span><span class="given-names" tagx="given-names" title="given-names">Donna</span></span><span class="contrib-id" tagx="contrib-id" title="contrib-id">https://orcid.org/0000-0003-4006-4650</span><a href="#jia225610-aff-0002"><sup>2</sup></a><a href="#jia225610-aff-0003"><sup>3</sup></a><span class="address" title="address"><span class="email" tagx="email" title="email">donna.spiegelman@yale.edu</span></span></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Walsh</span><span class="given-names" tagx="given-names" title="given-names">Fiona</span></span><a href="#jia225610-aff-0004"><sup>4</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mazibuko</span><span class="given-names" tagx="given-names" title="given-names">Sikhatele</span></span><a href="#jia225610-aff-0005"><sup>5</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Pasipamire</span><span class="given-names" tagx="given-names" title="given-names">Munyaradzi</span></span><a href="#jia225610-aff-0005"><sup>5</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chai</span><span class="given-names" tagx="given-names" title="given-names">Boyang</span></span><a href="#jia225610-aff-0006"><sup>6</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reis</span><span class="given-names" tagx="given-names" title="given-names">Ria</span></span><a href="#jia225610-aff-0007"><sup>7</sup></a><a href="#jia225610-aff-0008"><sup>8</sup></a><a href="#jia225610-aff-0009"><sup>9</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mlambo</span><span class="given-names" tagx="given-names" title="given-names">Khudzie</span></span><a href="#jia225610-aff-0001"><sup>1</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Delva</span><span class="given-names" tagx="given-names" title="given-names">Wim</span></span><a href="#jia225610-aff-0010"><sup>10</sup></a><a href="#jia225610-aff-0011"><sup>11</sup></a><a href="#jia225610-aff-0012"><sup>12</sup></a><a href="#jia225610-aff-0013"><sup>13</sup></a><a href="#jia225610-aff-0014"><sup>14</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khumalo</span><span class="given-names" tagx="given-names" title="given-names">Gavin</span></span><a href="#jia225610-aff-0015"><sup>15</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zwane</span><span class="given-names" tagx="given-names" title="given-names">Mandisa</span></span><a href="#jia225610-aff-0016"><sup>16</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fleming</span><span class="given-names" tagx="given-names" title="given-names">Yvette</span></span><a href="#jia225610-aff-0017"><sup>17</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mafara</span><span class="given-names" tagx="given-names" title="given-names">Emma</span></span><a href="#jia225610-aff-0001"><sup>1</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hettema</span><span class="given-names" tagx="given-names" title="given-names">Anita</span></span><a href="#jia225610-aff-0001"><sup>1</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lejeune</span><span class="given-names" tagx="given-names" title="given-names">Charlotte</span></span><a href="#jia225610-aff-0001"><sup>1</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Chao</span><span class="given-names" tagx="given-names" title="given-names">Ariel</span></span><a href="#jia225610-aff-0002"><sup>2</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">BÃ¤rnighausen</span><span class="given-names" tagx="given-names" title="given-names">Till</span></span><a href="#jia225610-aff-0018"><sup>18</sup></a><a href="#jia225610-aff-0019"><sup>19</sup></a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Okello</span><span class="given-names" tagx="given-names" title="given-names">Velephi</span></span><a href="#jia225610-aff-0020"><sup>20</sup></a></span></div><span class="citation_author_institution" id="jia225610-aff-0001">[1], <span class="institution" title="institution">Clinton Health Access Initiative (CHAI)</span><span class="city" tagx="city" title="city">Mbabane</span><span class="country" tagx="country" title="country">Swaziland</span></span><span class="citation_author_institution" id="jia225610-aff-0002">[2], <span class="named-content" title="named-content">Center on Methods for Implementation and Prevention Science and Department of Biostatistics</span><span class="institution" title="institution">Yale School of Public Health</span><span class="city" tagx="city" title="city">New Haven</span><span class="named-content" title="named-content">CT</span><span class="country" tagx="country" title="country">USA</span></span><span class="citation_author_institution" id="jia225610-aff-0003">[3], <span class="named-content" title="named-content">Departments of Epidemiology</span><span class="named-content" title="named-content">Biostatistics, Nutrition and Global Health</span><span class="institution" title="institution">Harvard T.H Chan School of Public Health</span><span class="city" tagx="city" title="city">Boston</span><span class="named-content" title="named-content">MA</span><span class="country" tagx="country" title="country">USA</span></span><span class="citation_author_institution" id="jia225610-aff-0004">[4], <span class="institution" title="institution">Clinton Health Access Initiative (CHAI)</span><span class="city" tagx="city" title="city">Boston</span><span class="named-content" title="named-content">MA</span><span class="country" tagx="country" title="country">USA</span></span><span class="citation_author_institution" id="jia225610-aff-0005">[5], <span class="named-content" title="named-content">Eswatini National ART program (SNAP)</span><span class="institution" title="institution">Ministry of Health</span><span class="city" tagx="city" title="city">Mbabane</span><span class="country" tagx="country" title="country">Swaziland</span></span><span class="citation_author_institution" id="jia225610-aff-0006">[6], <span class="named-content" title="named-content">Department of Nutrition</span><span class="institution" title="institution">Harvard T.H Chan School of Public Health</span><span class="city" tagx="city" title="city">Boston</span><span class="named-content" title="named-content">MA</span><span class="country" tagx="country" title="country">USA</span></span><span class="citation_author_institution" id="jia225610-aff-0007">[7], <span class="institution" title="institution">Leiden University Medical Center</span><span class="institution" title="institution">Leiden University</span><span class="city" tagx="city" title="city">Leiden</span><span class="country" tagx="country" title="country">the Netherlands</span></span><span class="citation_author_institution" id="jia225610-aff-0008">[8], <span class="named-content" title="named-content">Amsterdam Institute for Social Science</span><span class="institution" title="institution">University of Amsterdam</span><span class="city" tagx="city" title="city">Amsterdam</span><span class="country" tagx="country" title="country">the Netherlands</span></span><span class="citation_author_institution" id="jia225610-aff-0009">[9], <span class="named-content" title="named-content">Children's Institute</span><span class="institution" title="institution">University of Cape Town</span><span class="city" tagx="city" title="city">Cape Town</span><span class="country" tagx="country" title="country">South Africa</span></span><span class="citation_author_institution" id="jia225610-aff-0010">[10], <span class="named-content" title="named-content">The South African Department of Science and Technology â€� National Research Foundation (DSTâ€�NRF) Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA)</span><span class="institution" title="institution">Stellenbosch University</span><span class="city" tagx="city" title="city">Stellenbosch</span><span class="country" tagx="country" title="country">South Africa</span></span><span class="citation_author_institution" id="jia225610-aff-0011">[11], <span class="named-content" title="named-content">Center for Statistics</span><span class="institution" title="institution">Hasselt University</span><span class="city" tagx="city" title="city">Diepenbeek</span><span class="country" tagx="country" title="country">Belgium</span></span><span class="citation_author_institution" id="jia225610-aff-0012">[12], <span class="named-content" title="named-content">International Centre for Reproductive Health</span><span class="institution" title="institution">Ghent University</span><span class="city" tagx="city" title="city">Gent</span><span class="country" tagx="country" title="country">Belgium</span></span><span class="citation_author_institution" id="jia225610-aff-0013">[13], <span class="named-content" title="named-content">KU Leuven</span><span class="institution" title="institution">Rega Institute for Medical Research</span><span class="city" tagx="city" title="city">Leuven</span><span class="country" tagx="country" title="country">Belgium</span></span><span class="citation_author_institution" id="jia225610-aff-0014">[14], <span class="named-content" title="named-content">Department of Global Health</span><span class="named-content" title="named-content">Faculty of Medicine and Health Sciences</span><span class="institution" title="institution">Stellenbosch University</span><span class="city" tagx="city" title="city">Stellenbosch</span><span class="country" tagx="country" title="country">South Africa</span></span><span class="citation_author_institution" id="jia225610-aff-0015">[15], <span class="institution" title="institution">Eswatini National Network of People Living with HIV (SWANNEPHA)</span><span class="city" tagx="city" title="city">Mbabane</span><span class="country" tagx="country" title="country">Swaziland</span></span><span class="citation_author_institution" id="jia225610-aff-0016">[16], <span class="institution" title="institution">SAfAIDS</span><span class="city" tagx="city" title="city">Manzini</span><span class="country" tagx="country" title="country">Swaziland</span></span><span class="citation_author_institution" id="jia225610-aff-0017">[17], <span class="institution" title="institution">aidsfonds</span><span class="city" tagx="city" title="city">Amsterdam</span><span class="country" tagx="country" title="country">the Netherlands</span></span><span class="citation_author_institution" id="jia225610-aff-0018">[18], <span class="named-content" title="named-content">Heidelberg Institute of Public Health</span><span class="institution" title="institution">University of Heidelberg</span><span class="city" tagx="city" title="city">Heidelberg</span><span class="country" tagx="country" title="country">Germany</span></span><span class="citation_author_institution" id="jia225610-aff-0019">[19], <span class="named-content" title="named-content">Department of Global Health and Population</span><span class="institution" title="institution">Harvard T.H Chan School of Public Health</span><span class="city" tagx="city" title="city">Boston</span><span class="named-content" title="named-content">MA</span><span class="country" tagx="country" title="country">USA</span></span><span class="citation_author_institution" id="jia225610-aff-0020">[20], <span class="named-content" title="named-content">Directorate Office</span><span class="institution" title="institution">Ministry of Health</span><span class="city" tagx="city" title="city">Mbabane</span><span class="country" tagx="country" title="country">Swaziland</span></span><div class="author-notes" title="author-notes"> <div class="corresp" title="corresp"><span class="label" tagx="label" title="label">*</span><b>Corresponding author:</b> Donna Spiegelman, Yale School of Public Health, 60 College Street, New Haven, Connecticut 06510, USA. Tel: +1â€�617â€�835â€�5119. (<span class="email" tagx="email" title="email">donna.spiegelman@yale.edu</span>)<br /><br /></div> </div><span class="pub-date-epub" title="pub-date-epub">epub: <span>2020-9-9</span></span><span class="pub-date-collection" title="pub-date-collection">collection: <span>2020-9</span></span><span class="volume" tagx="volume" title="volume">23</span><span class="issue" tagx="issue" title="issue">9</span><span class="issue-id" tagx="issue-id" title="issue-id">10.1002/jia2.v23.9</span><span class="elocation-id" tagx="elocation-id" title="elocation-id">e25610</span><span class="history" title="history"><span class="received" title="received">received: 2019-10-22</span><span class="rev-recd" title="rev-recd">rev-recd: 2020-6-10</span><span class="accepted" title="accepted">accepted: 2020-7-15</span></span><div class="permissions"><span class="copyright" title="copyright">(C) , </span><span class="license" title="license"><span class="license-p" title="license-p">This is an open access article under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</span></span></div><a class="self-uri" href="file:JIA2-23-e25610.pdf" title="self-uri">file:JIA2-23-e25610.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <div class="introduction" title="sec"> <div class="title" tagx="title" title="title">
Introduction</div> <p>The WHO recommends antiretroviral treatment (ART) for all HIVâ€�positive patients regardless of CD4 count or disease stage, referred to as â€œEarly Access to ART for Allâ€� (EAAA). The health systems effects of EAAA implementation are unknown. This trial was implemented in a governmentâ€�managed public health system with the aim to examine the â€œreal worldâ€� impact of EAAA on care retention and viral suppression.</p> </div> <div class="methods" title="sec"> <div class="title" tagx="title" title="title">
Methods</div> <p>In this steppedâ€�wedge randomized controlled trial, 14 public sector health facilities in Eswatini were paired and randomly assigned to stepwise transition from standard of care (SoC) to EAAA. ARTâ€�naÃ¯ve participants â‰¥18Â years who were not pregnant or breastfeeding were eligible for enrolment. We used Cox proportional hazard models with censoring at clinic transition to estimate the effects of EAAA on retention in care and retention and viral suppression combined.</p> </div> <div class="results" title="sec"> <div class="title" tagx="title" title="title">
Results</div> <p>Between September 2014 and August 2017, 3405 participants were enrolled. In SoC and EAAA respectively, 12â€�month HIV care retention rates were 80% (95% CI: 77 to 83) and 86% (95% CI: 83 to 88). The 12â€�month combined retention and viral suppression endpoint rates were 44% (95% CI: 40 to 48) under SoC compared to 80% (95% CI: 77 to 83) under EAAA. EAAA increased both retention (HR: 1Â·60, 95% CI: 1Â·15 to 2Â·21, <i>p</i>Â =Â 0.005) and retention and viral suppression combined (HR: 4.88, 95% CI: 2.96 to 8.05, <i>p</i>Â <div class="â_UNKNOWN"> </div></p></div> <div class="conclusions" title="sec"> <div class="title" tagx="title" title="title">
Conclusions</div> <p>The observed improvement in retention in care and on the combined retention and viral suppression provides an important coâ€�benefit of EAAA to HIVâ€�positive adults themselves, at least in the short term. Our results from this â€œreal worldâ€� health systems trial strongly support EAAA for Eswatini and countries with similar HIV epidemics and health systems. VL monitoring needs to be scaled up for appropriate care management.</p> </div> </div> <div class="kwd-group"> <div class="kwd" title="kwd">
universal treatment</div> <div class="kwd" title="kwd">
HIV retention</div> <div class="kwd" title="kwd">
viral suppression</div> <div class="kwd" title="kwd">
Eswatini</div> <div class="kwd" title="kwd">
Subâ€�Saharan Africa</div> <div class="kwd" title="kwd">
antiretroviral therapy</div> </div> <div class="funding-group" title="funding-group"> <div class="funding" title="funding">
Funding</div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source">
Dutch Postcode Lottery, Netherlands</div> </div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source">
Clinton Health Access Initiative</div> </div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source"> <div class="institution-wrap" title="institution-wrap"><span class="institution" title="institution">National Institute of Child Health and Human Development </span><span class="institution-id" title="institution-id">10.13039/100000071</span></div> </div><span class="award-id" tagx="award-id" title="award-id">R01â€�HD084233</span></div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source">
Embassy of the Kingdom of the Netherlands in Mozambique</div> </div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source"> <div class="institution-wrap" title="institution-wrap"><span class="institution" title="institution">Alexander von Humboldtâ€�Stiftung </span><span class="institution-id" title="institution-id">10.13039/100005156</span></div> </div> </div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source">
National Institute of Aging, NIH</div><span class="award-id" tagx="award-id" title="award-id">P01â€�AG041710</span></div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source"> <div class="institution-wrap" title="institution-wrap"><span class="institution" title="institution">National Institute of Allergy and Infectious Diseases </span><span class="institution-id" title="institution-id">10.13039/100000060</span></div> </div><span class="award-id" tagx="award-id" title="award-id">R01â€�AI112339</span><span class="award-id" tagx="award-id" title="award-id">R01â€�AI124389</span></div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source"> <div class="institution-wrap" title="institution-wrap"><span class="institution" title="institution">European Commission </span><span class="institution-id" title="institution-id">10.13039/501100000780</span></div> </div> </div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source"> <div class="institution-wrap" title="institution-wrap"><span class="institution" title="institution">Wellcome Trust </span><span class="institution-id" title="institution-id">10.13039/100004440</span></div> </div> </div> <div class="award-group" title="award-group"> <div class="funding-source" title="funding-source"> <div class="institution-wrap" title="institution-wrap"><span class="institution" title="institution">Fogarty International Center </span><span class="institution-id" title="institution-id">10.13039/100000061</span></div> </div><span class="award-id" tagx="award-id" title="award-id">D43â€�TW009775</span></div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> <div class="custom-meta-group" title="custom-meta-group"> <meta name="source-schema-version-number" value="2.0" /> <meta name="cover-date" value="September 2020" /> <meta name="details-of-publishers-convertor" value="Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.1 mode:remove_FC converted:22.09.2020" /> </div> </div> <p content-type="self-citation"><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Khan</span>, <span class="given-names" tagx="given-names" title="given-names">S.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Spiegelman</span>, <span class="given-names" tagx="given-names" title="given-names">D.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Walsh</span>, <span class="given-names" tagx="given-names" title="given-names">F.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mazibuko</span>, <span class="given-names" tagx="given-names" title="given-names">S.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Pasipamire</span>, <span class="given-names" tagx="given-names" title="given-names">M.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chai</span>, <span class="given-names" tagx="given-names" title="given-names">B.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Reis</span>, <span class="given-names" tagx="given-names" title="given-names">R.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mlambo</span>, <span class="given-names" tagx="given-names" title="given-names">K.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Delva</span>, <span class="given-names" tagx="given-names" title="given-names">W.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Khumalo</span>, <span class="given-names" tagx="given-names" title="given-names">G.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zwane</span>, <span class="given-names" tagx="given-names" title="given-names">M.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Fleming</span>, <span class="given-names" tagx="given-names" title="given-names">Y.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mafara</span>, <span class="given-names" tagx="given-names" title="given-names">E.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hettema</span>, <span class="given-names" tagx="given-names" title="given-names">A.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lejeune</span>, <span class="given-names" tagx="given-names" title="given-names">C.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chao</span>, <span class="given-names" tagx="given-names" title="given-names">A.</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">BÃ¤rnighausen</span>, <span class="given-names" tagx="given-names" title="given-names">T.</span></span> and <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Okello</span>, <span class="given-names" tagx="given-names" title="given-names">V.</span></span><span class="mixed-article-title" title="mixed-article-title">Early access to antiretroviral therapy versus standard of care among HIVâ€�positive participants in Eswatini in the public health sector: the MaxART steppedâ€�wedge randomized controlled trial</span>. <span class="source" tagx="source" title="source">J Int AIDS Soc</span>. <span class="year" tagx="year" title="year">2020</span>; <span class="volume" tagx="volume" title="volume">23</span>(9):<span class="elocation-id" tagx="elocation-id" title="elocation-id">e25610</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32949103">32949103</a></span></span></p> <div class="fn-group" title="fn-group"> <div class="fn-type-" title=""> <p><b>Clinical trial number:</b> NCT02909218.</p> </div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1</span><div class="title" tagx="title" title="title">
Introduction</div> <p>In 2018, nearly 38Â million people were living with human immunodeficiency virus (HIV), of whom 20.64Â million live in subâ€�Saharan Africa. There has been a 56% decline in AIDSâ€�related deaths from the peak of 1.7Â million in 2004 to 770,000 in 2018, likely due to the threeâ€�fold increase in people receiving antiretroviral therapy (ART) since 2010 [<a href="#jia225610-bib-0001">1</a>]. While there has been significant progress to scale up HIV testing and treatment, the incidence of HIV infection remains high, with an estimated 1.7Â million newly infected people in 2018 [<a href="#jia225610-bib-0001">1</a>].</p> <p>The HPTN 052 trial was first to demonstrate that early antiretroviral (ART) initiation â€" referred to here as Early Assess to ART for All (EAAA) â€" prevents viral transmission to the uninfected partner in heterosexual HIVâ€�discordant couples [<a href="#jia225610-bib-0002">2</a>]. To understand if the reported efficacy of EAAA would have similar effectiveness in preventing transmission in subâ€�Saharan Africa, four large communityâ€�based trials were launched between 2011 and 2013 [<a href="#jia225610-bib-0003">3</a>, <a href="#jia225610-bib-0004">4</a>, <a href="#jia225610-bib-0005">5</a>, <a href="#jia225610-bib-0006">6</a>, <a href="#jia225610-bib-0007">7</a>, <a href="#jia225610-bib-0008">8</a>]. These trials demonstrated that there are significant implementation barriers to EAAA for reducing HIV incidence in highâ€�prevalence resourceâ€�limited settings.</p> <p>In 2014, the Eswatini Ministry of Health launched the MaxART steppedâ€�wedge randomized controlled trial to implement EAAA through the governmentâ€�managed health system. Eswatini has one of the highest HIV prevalence rates in the world, 27%, and an estimated annual incidence of 1.36% in adults [<a href="#jia225610-bib-0009">9</a>]. While the Eswatini Ministry of Health had made substantial progress in addressing their HIV epidemic, there was interest in identifying an effective, sustainable approach to reduce the infection rate. Without this reduction, the number of people needing HIV treatment in Eswatini will likely expand along with the treatment costs.</p> <p>In September 2015, the World Health Organization (WHO) recommended ART irrespective of CD4 count (EAAA) [<a href="#jia225610-bib-0010">10</a>]. As highâ€�prevalence countries adopt these new guidelines, the MaxART trial offers evidence about the â€œrealâ€�worldâ€� impact on retention and viral suppression under an EAAA approach. This trial is registered at clinicaltrials.gov (NCT02909218).</p> </div> <div class="methods" title="methods"><span class="label" tagx="label" title="label">2</span><div class="title" tagx="title" title="title">
Methods</div> <p>This trial was designed and conducted by the MaxART Consortium â€" led by the Eswatini Ministry of Health â€" from September 2014 to August 2017. The trial methods and power calculations have been reported elsewhere [<a href="#jia225610-bib-0011">11</a>]. Briefly, we implemented a clinicâ€�based steppedâ€�wedge design in which the participating 14 clinics were randomly assigned in pairs, matched by catchment size and geographic proximity, to shift from standard of care (SoC) to EAAA at preâ€�specified dates. After four months of baseline data collection in all clinics, one pair of clinics transitioned at each fourâ€�month step. The last pair was transitioned on 1 October 2016 instead of 1 January 2017, because on the former date, Eswatini changed its SoC from CD4Â â‰¤Â 500 to EAAA. This change was approved by the trialâ€™s Data Safety Monitoring Board, Advisory Board, Primary Research Team and the Eswatini Ministry of Health. The health workers, trial participants and trial staff were blinded to the timing of the clinic transition to minimize bias.</p> <div class="participants" title="sec"><span class="label" tagx="label" title="label">2.1</span><div class="title" tagx="title" title="title">
Participants</div> <p>ARTâ€�naÃ¯ve, nonâ€�pregnant or breastfeeding HIVâ€�positive participants, 18Â years of age or older, with no mental illness were eligible for the trial. Individuals who had already been initiated on ART before the start of the trial were excluded. All eligible participants were enrolled.</p> </div> <div class="standardofcare" title="sec"><span class="label" tagx="label" title="label">2.2</span><div class="title" tagx="title" title="title">
Standard of care</div> <p>Under SoC, participants meeting SoC ART eligibility criteria were referred for ART initiation, while those who did not were enrolled in preâ€�ART care. Preâ€�ART participants received followâ€�up appointments to reâ€�assess ART eligibility and screen for tuberculosis symptoms in threeâ€�month intervals. Over the course of the trial, changes to the national SoC for ART eligibility were incorporated into the trial implementation. Prior to 1 December 2015, the national ART initiation threshold was CD4Â â‰¤Â 350 and/or WHO Stage 3 or 4. On 1 December 2015, the threshold changed to CD4Â â‰¤Â 500 and/or WHO Stage 3 or 4, and on 1 October 2016, Eswatini adopted EAAA as SoC.</p> </div> <div class="earlyaccesstoartforall" title="sec"><span class="label" tagx="label" title="label">2.3</span><div class="title" tagx="title" title="title">
Early access to ART for all</div> <p>Under EAAA, all HIVâ€�positive trial participants were eligible for ART initiation irrespective of CD4 count or WHO stage. Prior to the intervention, there were community sensitization events with traditional leaders in the surrounding communities, and health talks and posters about EAAA at the participating clinics. Clinical mentors were also positioned at the participating facilities to support the nursing staff with the introduction of EAAA.</p> </div> <div class="measurements" title="sec"><span class="label" tagx="label" title="label">2.4</span><div class="title" tagx="title" title="title">
Measurements</div> <p>The primary endpoints â€" retention in HIV care and viral suppression six months or more after ART initiation among those retained â€" were chosen because they are proxy indicators for longâ€�term HIVâ€�related health outcomes, mortality and transmission [<a href="#jia225610-bib-0012">12</a>, <a href="#jia225610-bib-0013">13</a>]. We also present the effect of EAAA on a combined endpoint of retention and viral suppression. The results for several secondary endpoints (ART initiation, drug resistance, HIV diseases progression, cost per patient per year) for this trial are in preparation or under review at this time. The results for patient satisfaction, adherence and mortality have been published elsewhere [<a href="#jia225610-bib-0014">14</a>, <a href="#jia225610-bib-0015">15</a>, <a href="#jia225610-bib-0016">16</a>].</p> <p>The operational definitions of the primary endpoints, retention and viral suppression, were established according to the definitions outlined by the Eswatini Ministry of Health Integrated HIV Management Guidelines 2015 (TableÂ <a href="#jia225610-tbl-0001">1</a>). See FiguresÂ <a href="#jia225610-sup-0001">S1</a> and <a href="#jia225610-sup-0001">S2</a> for further details about these definitions. The combined endpoint was defined as the date when either nonâ€�retention in care or elevated viral load (VL) occurred, and survival time was the minimum of the times from enrolment to any events qualifying for nonâ€�retention or elevated VL. Unlike viral suppression, which considers the patients who survived six months or more beyond ARTâ€�initiation, the combined endpoint is a fully randomized endpoint.</p> <div class="table-wrap_UNKNOWN" id="jia225610-tbl-0001" content-type="Table" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1</span> <p>Endpoint definitions</p>  <table frame="hsides" rules="groups"> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <thead valign="top"> <tr style="border-bottom:solid 1px #000000"> <th align="left" valign="top" rowspan="1" colspan="1">Primary endpoint</th> <th align="left" valign="top" rowspan="1" colspan="1">Definition</th> <th align="left" valign="top" rowspan="1" colspan="1">Additional considerations</th> </tr> </thead> <tbody> <tr> <td align="left" rowspan="1" colspan="1">Retention</td> <td align="left" rowspan="1" colspan="1"> <p>Participant is classified as retained in HIV care if they are a) alive and b) have not stopped treatment, whereby either:</p> <ul> <li> <p>[End of the Study Period]â€�[Last Visit Date] &amp;lt; 90Â days; or</p> </li> <li> <p>[Next Appointment Date] â€" [End of the Study Period]&amp;gt; (within 30Â days)</p> </li> </ul> <p>Time to nonâ€�retention was the last date at which the first of the above defining events occurred.</p> </td> <td align="left" rowspan="1" colspan="1"> <ul> <li> <p>If the next scheduled visit date is missing, then the next visit date will equal last visit date plus 120Â days</p> </li> <li> <p>For participants who transferred out or stopped treatment, their last visit date was used as their transfer date or stopped treatment date</p> </li> </ul> </td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Viral suppression</td> <td align="left" rowspan="1" colspan="1"> <p>Participants were excluded if:</p> <ul> <li> <p>They were not retained for 180Â days following ART initiation; or</p> </li> <li> <p>They were transferred out of the MaxART trial clinics by 180Â days following ART initiation; or</p> </li> <li> <p>They were never initiated on ART; or</p> </li> <li> <p>The time between ART initiation and the study end date was &amp;lt;180Â days</p> </li> </ul> <p>Nonâ€�excluded participants were classified as virally unsuppressed when one of the following was true:</p> <ul> <li> <p>The first VL measurement was â‰¥1000Â copies/mml; or</p> </li> <li> <p>They were lost to followâ€�up by the end of the study or the clinic transition date; or</p> </li> <li> <p>They stopped treatment; or</p> </li> <li> <p>Their death was ARTâ€� or HIVâ€�related; or</p> </li> <li> <p>There was no available VL measurement</p> </li> </ul> </td> <td align="left" rowspan="1" colspan="1"> <ul> <li> <p>This endpoint assesses viral suppression conditional on ARTâ€�initiation and retention to 180Â days post ART initiation date</p> </li> <li> <p>Time to elevated VL 180Â days postâ€�ART initiation was the date at which the first of these defining events occurred. As such, it is not a randomized endpoint</p> </li> <li> <p>When one or more VL measurements were available six months or more after ART initiation, we took the last available VL prior to censoring as the eventâ€�defining value, assuming that if suppressed in the future, they were suppressed in the past</p> </li> </ul> </td> </tr> <tr> <td align="left" rowspan="1" colspan="1">Combined retention and viral suppression</td> <td align="left" rowspan="1" colspan="1"> <p>Defined as:</p> <ul> <li> <p>Date when either nonâ€�retention in care or elevated VL occurred, and</p> </li> <li> <p>Survival time was the minimum of the times from enrolment to any of the events qualifying for either nonâ€�retention or elevated VL</p> </li> </ul> </td> <td align="left" rowspan="1" colspan="1"> <ul> <li> <p>While this combined endpoint was not one of the original primary endpoints registered for the trial, it offers important insights and was included in the final analysis</p> </li> <li> <p>The combined endpoint was analysed using an intentâ€�toâ€�treat approach</p> </li> </ul> </td> </tr> </tbody> </table> <div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">John Wiley &amp;amp; Sons, Ltd</span>, </span></div> </div> </div> <div class="datacollectionandmanagement" title="sec"><span class="label" tagx="label" title="label">2.5</span><div class="title" tagx="title" title="title">
Data collection and management</div> <p>We measured the endpoints using routine data extracted from the participantsâ€™ clinical records. We developed standard operating procedures for data management for transferring participant paper files to a trialâ€�specific electronic database. Nurse mentors regularly reviewed the participant files for accuracy and completeness, and provided mentorship to the clinic staff. The data manager and trial statistician generated monthly error reports for data clerks and nurse mentors to resolve in the clinics. In addition, the data manager conducted a quarterly quality assessment by reviewing 10% of paper records with electronic data entry.</p> </div> <div class="statisticalanalysis" title="sec"><span class="label" tagx="label" title="label">2.6</span><div class="title" tagx="title" title="title">
Statistical analysis</div> <p>We used Cox proportional hazard models for clustered data to estimate the effect size, confidence intervals and <i>p</i>â€�values whenever betweenâ€�facility intraâ€�class correlations (ICCs) were greater than or equal to 0.01 [<a href="#jia225610-bib-0017">17</a>, <a href="#jia225610-bib-0018">18</a>]. Given the small number of facilities, with very small ICCs, robust variances gave unrealistically small <i>p</i>â€�values [<a href="#jia225610-bib-0019">19</a>]. Because there were a small number of facilities randomized, residual confounding is possible. Thus, we conducted multivariableâ€�adjusted analyses, where we considered known and suspected baseline determinants of retention and viral suppression, and included those with <i>p</i>Â <div class="â_UNKNOWN" href="#jia225610-bib-0020">
20]. Steptime was adjusted for in all analyses, to ensure that any background time trends related to quality of care or disease epidemiology did not lead to spurious differences between the two groups. Survival curves used the Breslow estimator and therefore needed to be estimated at specific covariate values in the multivariate Cox model from where the estimator was derived. The value of each covariate, including steptime, was set at the mean value of each personâ€�visit in the study population (TableÂ <a href="#jia225610-tbl-0002">2</a>). Stepwise restricted cubic splines were used to model continuous covariates, to reduces bias due to incorrect assumptions about linearity of the covariateâ€�outcome relationships [<a href="#jia225610-bib-0021">21</a>]. To further adjust for any bias due to time trends not addressed by the categorical steptime variable, when calendar time as a linear or nonâ€�linear effect was significant at <i>p</i>Â <div class="â_UNKNOWN" href="#jia225610-bib-0022">
22]. In sensitivity analyses for the viral suppression endpoint, Fine and Gray competing risk methods were used, treating mortality not HIVâ€� or ARTâ€�related as competing risks [<a href="#jia225610-bib-0023">23</a>]. Confidence intervals and <i>p</i>â€�values were not adjusted for multiplicity [<a href="#jia225610-bib-0024">24</a>]. Effect modification was assessed by the robust score test, accounting for withinâ€�facility correlation of the outcomes. Analysis of effect modification was conducted among the subset of participants not missing each covariate and adjusted for the baseline covariates given in Footnote 1 of TablesÂ <a href="#jia225610-sup-0001">S1</a>,<a href="#jia225610-sup-0001">S2</a>,<a href="#jia225610-sup-0001">S3</a>.</div></div></p> <div class="table-wrap_UNKNOWN" id="jia225610-tbl-0002" content-type="Table" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 2</span> <p>Basic characteristics of MaxART participants at the time of trial enrolment</p>  <table frame="hsides" rules="groups"> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <thead valign="top"> <tr style="border-bottom:solid 1px #000000"> <th align="left" valign="top" rowspan="1" colspan="1" /> <th align="left" valign="top" rowspan="1" colspan="1">Standard of Care (nÂ =Â 2034)</th> <th align="left" valign="top" rowspan="1" colspan="1">EAAA (nÂ =Â 1371)</th> <th align="left" valign="top" rowspan="1" colspan="1">All ART naÃ¯ve (nÂ =Â 3405)</th> </tr> </thead> <tbody> <tr> <td align="left" colspan="4" rowspan="1">Demographic characteristics</td> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age at trial enrolment (year) median (q1, q3)</td> <td align="left" rowspan="1" colspan="1">33 (28, 42)</td> <td align="left" rowspan="1" colspan="1">33 (27, 40)</td> <td align="left" rowspan="1" colspan="1">33 (27, 41)</td> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age group (years) n (%)</td> <td align="left" rowspan="1" colspan="1" /> <td align="left" rowspan="1" colspan="1" /> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">18 to &amp;lt;20</td> <td align="left" rowspan="1" colspan="1">40 (2%)</td> <td align="left" rowspan="1" colspan="1">34 (3%)</td> <td align="left" rowspan="1" colspan="1">74 (2%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">20 to &amp;lt;30</td> <td align="left" rowspan="1" colspan="1">679 (33%)</td> <td align="left" rowspan="1" colspan="1">472 (34%)</td> <td align="left" rowspan="1" colspan="1">1151 (34%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">30 to &amp;lt;40</td> <td align="left" rowspan="1" colspan="1">722 (36%)</td> <td align="left" rowspan="1" colspan="1">500 (36%)</td> <td align="left" rowspan="1" colspan="1">1222 (36%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">40 to &amp;lt;50</td> <td align="left" rowspan="1" colspan="1">354 (17%)</td> <td align="left" rowspan="1" colspan="1">230 (17%)</td> <td align="left" rowspan="1" colspan="1">584 (17%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">50 to &amp;lt;60</td> <td align="left" rowspan="1" colspan="1">156 (8%)</td> <td align="left" rowspan="1" colspan="1">97 (7%)</td> <td align="left" rowspan="1" colspan="1">253 (7%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">60+</td> <td align="left" rowspan="1" colspan="1">83 (4%)</td> <td align="left" rowspan="1" colspan="1">38 (3%)</td> <td align="left" rowspan="1" colspan="1">121 (4%)</td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">Sex n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Male</td> <td align="left" rowspan="1" colspan="1">695 (34%)</td> <td align="left" rowspan="1" colspan="1">603 (44%)</td> <td align="left" rowspan="1" colspan="1">1298 (38%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Female</td> <td align="left" rowspan="1" colspan="1">1339 (66%)</td> <td align="left" rowspan="1" colspan="1">768 (56%)</td> <td align="left" rowspan="1" colspan="1">2107 (62%)</td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">Marital status n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Married</td> <td align="left" rowspan="1" colspan="1">1045 (52%)</td> <td align="left" rowspan="1" colspan="1">634 (48%)</td> <td align="left" rowspan="1" colspan="1">1679 (51%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Divorced/widowed</td> <td align="left" rowspan="1" colspan="1">127 (7%)</td> <td align="left" rowspan="1" colspan="1">78 (6%)</td> <td align="left" rowspan="1" colspan="1">205 (6%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Single</td> <td align="left" rowspan="1" colspan="1">825 (41%)</td> <td align="left" rowspan="1" colspan="1">614 (46%)</td> <td align="left" rowspan="1" colspan="1">1439 (43%)</td> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Marital status missing, n (%)</td> <td align="left" rowspan="1" colspan="1">37 (2%)</td> <td align="left" rowspan="1" colspan="1">45 (3%)</td> <td align="left" rowspan="1" colspan="1">82 (2%)</td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">Education n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Illiterate/primary</td> <td align="left" rowspan="1" colspan="1">589 (40%)</td> <td align="left" rowspan="1" colspan="1">384 (38%)</td> <td align="left" rowspan="1" colspan="1">973 (39%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Secondary</td> <td align="left" rowspan="1" colspan="1">438 (30%)</td> <td align="left" rowspan="1" colspan="1">362 (36%)</td> <td align="left" rowspan="1" colspan="1">800 (32%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">High school</td> <td align="left" rowspan="1" colspan="1">401 (27%)</td> <td align="left" rowspan="1" colspan="1">218 (22%)</td> <td align="left" rowspan="1" colspan="1">619 (25%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Tertiary</td> <td align="left" rowspan="1" colspan="1">48 (3%)</td> <td align="left" rowspan="1" colspan="1">37 (4%)</td> <td align="left" rowspan="1" colspan="1">85 (4%)</td> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Education missing, n (%)</td> <td align="left" rowspan="1" colspan="1">558 (27%)</td> <td align="left" rowspan="1" colspan="1">370 (27%)</td> <td align="left" rowspan="1" colspan="1">928 (27%)</td> </tr> <tr> <td align="left" colspan="4" rowspan="1">Clinical characteristics<a href="#jia225610-note-0002"><sup>a</sup></a></td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">BMI (kg/m<sup>2</sup>) n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">&amp;lt;18.5</td> <td align="left" rowspan="1" colspan="1">82 (4%)</td> <td align="left" rowspan="1" colspan="1">81 (6%)</td> <td align="left" rowspan="1" colspan="1">163 (5%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">18.5 to &amp;lt;25</td> <td align="left" rowspan="1" colspan="1">971 (49%)</td> <td align="left" rowspan="1" colspan="1">762 (57%)</td> <td align="left" rowspan="1" colspan="1">1733 (52%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">25 to &amp;lt;30</td> <td align="left" rowspan="1" colspan="1">529 (27%)</td> <td align="left" rowspan="1" colspan="1">281 (21%)</td> <td align="left" rowspan="1" colspan="1">810 (25%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">â‰¥30</td> <td align="left" rowspan="1" colspan="1">387 (20%)</td> <td align="left" rowspan="1" colspan="1">212 (16%)</td> <td align="left" rowspan="1" colspan="1">599 (18%)</td> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">BMI missing n (%)</td> <td align="left" rowspan="1" colspan="1">65 (3%)</td> <td align="left" rowspan="1" colspan="1">35 (3%)</td> <td align="left" rowspan="1" colspan="1">100 (3%)</td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">CD4 (cells/Î¼L) n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">&amp;lt;350</td> <td align="left" rowspan="1" colspan="1">804 (44%)</td> <td align="left" rowspan="1" colspan="1">632 (56%)</td> <td align="left" rowspan="1" colspan="1">1436 (49%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">350 to 500</td> <td align="left" rowspan="1" colspan="1">441 (24%)</td> <td align="left" rowspan="1" colspan="1">224 (20%)</td> <td align="left" rowspan="1" colspan="1">665 (22%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">&amp;gt;500</td> <td align="left" rowspan="1" colspan="1">591 (32%)</td> <td align="left" rowspan="1" colspan="1">266 (24%)</td> <td align="left" rowspan="1" colspan="1">857 (29%)</td> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">CD4 missing n (%)</td> <td align="left" rowspan="1" colspan="1">198 (10%)</td> <td align="left" rowspan="1" colspan="1">249 (18%)</td> <td align="left" rowspan="1" colspan="1">447 (13%)</td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">WHO stage n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">1</td> <td align="left" rowspan="1" colspan="1">1074 (63%)</td> <td align="left" rowspan="1" colspan="1">800 (63%)</td> <td align="left" rowspan="1" colspan="1">1874 (63%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">2</td> <td align="left" rowspan="1" colspan="1">357 (21%)</td> <td align="left" rowspan="1" colspan="1">320 (25%)</td> <td align="left" rowspan="1" colspan="1">677 (23%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">3 or 4</td> <td align="left" rowspan="1" colspan="1">264 (16%)</td> <td align="left" rowspan="1" colspan="1">146 (12%)</td> <td align="left" rowspan="1" colspan="1">410 (14%)</td> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">WHO stage missing n (%)</td> <td align="left" rowspan="1" colspan="1">339 (17%)</td> <td align="left" rowspan="1" colspan="1">105 (8%)</td> <td align="left" rowspan="1" colspan="1">444 (13%)</td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">Screened for TB symptoms n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Positive</td> <td align="left" rowspan="1" colspan="1">190 (10%)</td> <td align="left" rowspan="1" colspan="1">100 (8%)</td> <td align="left" rowspan="1" colspan="1">290 (9%)</td> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Missing screening for TB symptoms n (%)</td> <td align="left" rowspan="1" colspan="1">82 (4%)</td> <td align="left" rowspan="1" colspan="1">66 (5%)</td> <td align="left" rowspan="1" colspan="1">148 (4%)</td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">Viral load (copies/ml) n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">&amp;lt;1000</td> <td align="left" rowspan="1" colspan="1">229 (12%)</td> <td align="left" rowspan="1" colspan="1">120 (10%)</td> <td align="left" rowspan="1" colspan="1">349 (11%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">1000 to &amp;lt;50â€š000</td> <td align="left" rowspan="1" colspan="1">781 (42%)</td> <td align="left" rowspan="1" colspan="1">479 (40%)</td> <td align="left" rowspan="1" colspan="1">1260 (41%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">50â€š000 to &amp;lt;100â€š000</td> <td align="left" rowspan="1" colspan="1">213 (11%)</td> <td align="left" rowspan="1" colspan="1">150 (13%)</td> <td align="left" rowspan="1" colspan="1">363 (12%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">â‰¥100â€š000</td> <td align="left" rowspan="1" colspan="1">661 (35%)</td> <td align="left" rowspan="1" colspan="1">438 (37%)</td> <td align="left" rowspan="1" colspan="1">1099 (36%)</td> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Viral load missing n (%)</td> <td align="left" rowspan="1" colspan="1">150 (7%)</td> <td align="left" rowspan="1" colspan="1">184 (13%)</td> <td align="left" rowspan="1" colspan="1">334 (10%)</td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">Time between positive HIV test to trial enrolment (years) n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">â‰¤1</td> <td align="left" rowspan="1" colspan="1">1189 (59%)</td> <td align="left" rowspan="1" colspan="1">1076 (79%)</td> <td align="left" rowspan="1" colspan="1">2265 (67%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">1 to â‰¤3</td> <td align="left" rowspan="1" colspan="1">421 (21%)</td> <td align="left" rowspan="1" colspan="1">134 (10%)</td> <td align="left" rowspan="1" colspan="1">555 (16%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">&amp;gt;3</td> <td align="left" rowspan="1" colspan="1">413 (20%)</td> <td align="left" rowspan="1" colspan="1">144 (11%)</td> <td align="left" rowspan="1" colspan="1">557 (17%)</td> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">Time from trial enrolment to ART initiation (months), median (q1, q3)</td> <td align="left" rowspan="1" colspan="1">11 (5, 16)</td> <td align="left" rowspan="1" colspan="1">0 (0, 0)</td> <td align="left" rowspan="1" colspan="1">7 (0, 88)</td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">Access to HIV Treatment supporter n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Yes</td> <td align="left" rowspan="1" colspan="1">1980 (97%)</td> <td align="left" rowspan="1" colspan="1">1339 (98%)</td> <td align="left" rowspan="1" colspan="1">3319 (97%)</td> </tr> <tr> <td align="left" colspan="4" rowspan="1">Clinic characteristics</td> </tr> <tr> <td align="left" style="padding-left:10%" colspan="4" rowspan="1">Level of clinic n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Hospital</td> <td align="left" rowspan="1" colspan="1">449 (22%)</td> <td align="left" rowspan="1" colspan="1">349 (26%)</td> <td align="left" rowspan="1" colspan="1">798 (23%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Clinic with maternity ward</td> <td align="left" rowspan="1" colspan="1">317 (16%)</td> <td align="left" rowspan="1" colspan="1">181 (13%)</td> <td align="left" rowspan="1" colspan="1">498 (15%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">Clinic without maternity ward</td> <td align="left" rowspan="1" colspan="1">1268 (62%)</td> <td align="left" rowspan="1" colspan="1">841 (61%)</td> <td align="left" rowspan="1" colspan="1">2109 (62%)</td> </tr> <tr> <td align="left" colspan="4" rowspan="1">Clinic volume by ART visits at baseline<a href="#jia225610-note-0003"><sup>b</sup></a> n (%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">&amp;lt; Median (400 visits)</td> <td align="left" rowspan="1" colspan="1">915 (45%)</td> <td align="left" rowspan="1" colspan="1">385 (28%)</td> <td align="left" rowspan="1" colspan="1">1300 (38%)</td> </tr> <tr> <td align="left" style="padding-left:15%" rowspan="1" colspan="1">â‰¥ Median (400 visits)</td> <td align="left" rowspan="1" colspan="1">1119 (55%)</td> <td align="left" rowspan="1" colspan="1">986 (72%)</td> <td align="left" rowspan="1" colspan="1">2105 (62%)</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN" id="jia225610-ntgp-0002"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>a</sup></span><p>Values within 90Â days of enrolment and before ART initiation</p> </div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>b</sup></span><p>ART participant visits received during the first quarter into trial. Median number of visits during this period is 400.</p> </div> </div> <div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">John Wiley &amp;amp; Sons, Ltd</span>, </span></div> </div> <p>The combined endpoint is a means of considering the impact of the intervention on viral suppression with less need for assumptions about those missing VLs. It has been reported that 91.9% of those who report being on ART are virally suppressed [<a href="#jia225610-bib-0025">25</a>]. Thus, in sensitivity analysis, we varied the unsuppression rate among those missing VLs from 5% to 10% to 20%, randomly assigning those who experience the combined endpoint through missing VL to being considered unsuppressed at the assumed percentage.</p> </div> <div class="ethicalapproval" title="sec"><span class="label" tagx="label" title="label">2.7</span><div class="title" tagx="title" title="title">
Ethical approval</div> <p>The trial was approved by the Eswatini National Health Research Review Board on 17 July 2014 (MH/599C/FWA 000 15 267).</p> </div> </div> <div class="results" title="results"><span class="label" tagx="label" title="label">3</span><div class="title" tagx="title" title="title">
Results</div> <p>The trial was conducted between September 2014 and August 2017, during which 3485 participants were enrolled. Following <i>a priori</i> exclusion criteria, 80 (2%) participants were excluded, leaving 3405 eligible participants, of whom 2034 (60%) enrolled during the SoC phase of their clinic and 1371 (40%) under EAAA (FigureÂ <a href="#jia225610-fig-0001">1</a>). From the distribution of enrolment by clinic and step, we observed a larger sample size in the earlier steps because existing preâ€�ART participants were enrolled into the trial, whereas at later steps of the trial, only participants who were newly diagnosed or who had previously disengaged from preâ€�ART care remained available for enrolment (FigureÂ <a href="#jia225610-fig-0002">2</a>). Consequently, there were more participants in SoC than EAAA.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1</span></a></div>   <p>Flow diagram of participants enrolled during the control and intervention phases MaxART</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 2</span></a></div>   <p>Number of enrolled participants by clinic pairs and steps. *Eswatini national guidelines for ART initiation changed from a CD4 count threshold ofÂ â‰¤Â 350 cells/Î¼L toÂ â‰¤Â 500 cells/Î¼L on December 1, 2016. **Eswatiniâ€™s national ART guidelines for ART initiation changed a CD4 count threshold ofÂ â‰¤Â 500 cells/Î¼L or less to a universal test and treat approach on 1 October 2016</p>   </div> <p>Demographic characteristics did not vary appreciably between the two study arms, with the exception of sex (34% SoC and 44% EAAA of the enrolled participants were male). Most clinical characteristics did vary between the study arms. Notably, 79% of participants enrolled within a year of HIV diagnosis in EAAA, compared to 49% in SoC, and 56% enrolled with baseline CD4Â â‰¤Â 350 in EAAA compared to 44% in SoC (TableÂ <a href="#jia225610-tbl-0002">2</a>).</p> <p>TableÂ <a href="#jia225610-tbl-0003">3</a> provides the steptimeâ€�adjusted incidence rates and hazard ratios for the three endpoints. In SoC and EAAA, respectively, the 12â€�month retention rates were 80% (95% confidence interval (CI): 77 to 83) and 86% (95% CI: 83 to 88) (FigureÂ <a href="#jia225610-fig-0003">3</a>). Under EAAA compared to SoC, a 60% significant improvement in retention was observed (HR: 1.60, 95% CI: 1.15 to 2.21, <i>p</i>Â =Â 0.005) (TableÂ <a href="#jia225610-tbl-0003">3</a>). Although VL coverage was low in both the SoC and EAAA arms with 80% and 66% of participants not receiving a VL between 180Â days postâ€�ART initiation and end of followâ€�up, significant improvements of increased viral suppression were also observed with EAAA compared to SoC (HR: 14.51, 95% CI: 7.31 to 28.79, <i>p</i>Â <div class="â_UNKNOWN" href="#jia225610-sup-0001">
S3). Lastly, estimates for the combined endpoint can be interpreted as an assessment of the impact of the intervention on the third 90 of the HIV care cascade [<a href="#jia225610-bib-0026">26</a>, <a href="#jia225610-bib-0027">27</a>]. At one year, the cumulative incidence of retention and viral suppression was 44% (95% CI: 40 to 48) under SoC compared to 80% (95% CI: 77 to 83) under EAAA, and at two years, it was 5% (95% CI: 3 to 9) under SoC compared to 60% (95% CI: 56 to 65) under EAAA (FigureÂ <a href="#jia225610-sup-0001">S4</a>). EAAA led to a large significant increase in the combined endpoint (HR: 4.88, 95% CI: 2.96 to 8.05, <i>p</i>Â <div class="â_UNKNOWN" href="#jia225610-tbl-0003">
3).</div></div></p> <div class="table-wrap_UNKNOWN" id="jia225610-tbl-0003" content-type="Table" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 3</span> <p>The effect of EAAA on retention and viral suppression six months post ART initiation</p>  <table frame="hsides" rules="groups"> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <colgroup><col style="border-right:solid 1px #000000" span="1" /></colgroup> <thead valign="bottom"> <tr style="border-bottom:solid 1px #000000"> <th align="left" rowspan="2" valign="bottom" colspan="1">Population</th> <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Control</th> <th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Intervention</th> <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Steptime adjusted</th> <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Multivariable adjusted</th> <th align="left" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1" colspan="1" /> </tr> <tr style="border-bottom:solid 1px #000000"> <th align="left" valign="bottom" rowspan="1" colspan="1">Number of Failures</th> <th align="left" valign="bottom" rowspan="1" colspan="1">Followâ€�up time (personâ€�years)</th> <th align="left" valign="bottom" rowspan="1" colspan="1">Rate per personâ€�year</th> <th align="left" valign="bottom" rowspan="1" colspan="1">Number of Failures</th> <th align="left" valign="bottom" rowspan="1" colspan="1">Followâ€�up time (personâ€�years)</th> <th align="left" valign="bottom" rowspan="1" colspan="1">Rate per personâ€�year</th> <th align="left" valign="bottom" rowspan="1" colspan="1">HR (95%CI)<a href="#jia225610-note-0004"><sup>a</sup></a></th> <th align="left" valign="bottom" rowspan="1" colspan="1"><i>p</i>â€�value<a href="#jia225610-note-0005"><sup>b</sup></a></th> <th align="left" valign="bottom" rowspan="1" colspan="1">HR (95%CI)<a href="#jia225610-note-0004"><sup>a</sup></a></th> <th align="left" valign="bottom" rowspan="1" colspan="1"><i>p</i>â€�value<a href="#jia225610-note-0005"><sup>b</sup></a></th> <th align="left" valign="bottom" rowspan="1" colspan="1" /> </tr> </thead> <tbody> <tr> <td align="left" colspan="11" rowspan="1">Retention</td> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">All enrolled participants</td> <td align="left" rowspan="1" colspan="1">316</td> <td align="left" rowspan="1" colspan="1">1665.7</td> <td align="left" rowspan="1" colspan="1">0.19</td> <td align="left" rowspan="1" colspan="1">215</td> <td align="left" rowspan="1" colspan="1">1364.6</td> <td align="left" rowspan="1" colspan="1">0.16</td> <td align="left" rowspan="1" colspan="1">1.60 (1.15 to 2.21)</td> <td align="left" rowspan="1" colspan="1">0.005</td> <td align="left" rowspan="1" colspan="1">1.94 (1.33 to 2.82)<a href="#jia225610-note-0006"><sup>c</sup></a></td> <td align="left" rowspan="1" colspan="1">0.0006</td> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">SoCâ€�ineligible</td> <td align="left" rowspan="1" colspan="1">150</td> <td align="left" rowspan="1" colspan="1">851.7</td> <td align="left" rowspan="1" colspan="1">0.18</td> <td align="left" rowspan="1" colspan="1">48</td> <td align="left" rowspan="1" colspan="1">399.6</td> <td align="left" rowspan="1" colspan="1">0.12</td> <td align="left" rowspan="1" colspan="1">1.89 (1.21 to 2.96)</td> <td align="left" rowspan="1" colspan="1">0.005</td> <td align="left" rowspan="1" colspan="1">2.75 (1.69 to 4.50)<a href="#jia225610-note-0007"><sup>d</sup></a></td> <td align="left" rowspan="1" colspan="1">&amp;lt;0.0001</td> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">SoCâ€�eligible</td> <td align="left" rowspan="1" colspan="1">138</td> <td align="left" rowspan="1" colspan="1">661.9</td> <td align="left" rowspan="1" colspan="1">0.21</td> <td align="left" rowspan="1" colspan="1">117</td> <td align="left" rowspan="1" colspan="1">839.7</td> <td align="left" rowspan="1" colspan="1">0.14</td> <td align="left" rowspan="1" colspan="1">1.79 (1.20 to 2.66)</td> <td align="left" rowspan="1" colspan="1">0.004</td> <td align="left" rowspan="1" colspan="1">1.84 (1.28 to 2.65)<a href="#jia225610-note-0006"><sup>c</sup></a></td> <td align="left" rowspan="1" colspan="1">0.0009</td> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" colspan="11" rowspan="1">Viral suppression six months post ART initiation</td> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">All enrolled participants</td> <td align="left" rowspan="1" colspan="1">352</td> <td align="left" rowspan="1" colspan="1">386.9</td> <td align="left" rowspan="1" colspan="1">0.91</td> <td align="left" rowspan="1" colspan="1">308</td> <td align="left" rowspan="1" colspan="1">691.1</td> <td align="left" rowspan="1" colspan="1">0.45</td> <td align="left" rowspan="1" colspan="1">14.51 (7.31 to 28.79)</td> <td align="left" rowspan="1" colspan="1">&amp;lt;0.0001</td> <td align="left" rowspan="1" colspan="1">22.08 (7.91 to 61.59)<a href="#jia225610-note-0008"><sup>e</sup></a></td> <td align="left" rowspan="1" colspan="1">&amp;lt;0.0001</td> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">SoCâ€�ineligible</td> <td align="left" rowspan="1" colspan="1">114</td> <td align="left" rowspan="1" colspan="1">121.9</td> <td align="left" rowspan="1" colspan="1">0.94</td> <td align="left" rowspan="1" colspan="1">65</td> <td align="left" rowspan="1" colspan="1">232.7</td> <td align="left" rowspan="1" colspan="1">0.28</td> <td align="left" rowspan="1" colspan="1">13.79 (6.11 to 31.11)</td> <td align="left" rowspan="1" colspan="1">&amp;lt;0.0001</td> <td align="left" rowspan="1" colspan="1">19.91 (6.14 to 64.61)<a href="#jia225610-note-0008"><sup>e</sup></a></td> <td align="left" rowspan="1" colspan="1">&amp;lt;0.0001</td> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">SoCâ€�eligible</td> <td align="left" rowspan="1" colspan="1">225</td> <td align="left" rowspan="1" colspan="1">249.5</td> <td align="left" rowspan="1" colspan="1">0.90</td> <td align="left" rowspan="1" colspan="1">205</td> <td align="left" rowspan="1" colspan="1">428.4</td> <td align="left" rowspan="1" colspan="1">0.48</td> <td align="left" rowspan="1" colspan="1">16.18 (8.31 to 31.51)</td> <td align="left" rowspan="1" colspan="1">&amp;lt;0.0001</td> <td align="left" rowspan="1" colspan="1">30.86 (8.89 to 107.20)<a href="#jia225610-note-0009"><sup>f</sup></a></td> <td align="left" rowspan="1" colspan="1">&amp;lt;0.0001</td> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" colspan="11" rowspan="1">Combined retention and viral suppression</td> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">All enrolled participants</td> <td align="left" rowspan="1" colspan="1">723</td> <td align="left" rowspan="1" colspan="1">1649.8</td> <td align="left" rowspan="1" colspan="1">0.44</td> <td align="left" rowspan="1" colspan="1">516</td> <td align="left" rowspan="1" colspan="1">1332.2</td> <td align="left" rowspan="1" colspan="1">0.39</td> <td align="left" rowspan="1" colspan="1">4.88 (2.96 to 8.05)</td> <td align="left" rowspan="1" colspan="1" /> <td align="left" rowspan="1" colspan="1">6.90 (3.11 to 15.31)<a href="#jia225610-note-0010"><sup>g</sup></a></td> <td align="left" rowspan="1" colspan="1" /> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">SoCâ€�ineligible</td> <td align="left" rowspan="1" colspan="1">275</td> <td align="left" rowspan="1" colspan="1">847.8</td> <td align="left" rowspan="1" colspan="1">0.32</td> <td align="left" rowspan="1" colspan="1">110</td> <td align="left" rowspan="1" colspan="1">395.2</td> <td align="left" rowspan="1" colspan="1">0.28</td> <td align="left" rowspan="1" colspan="1">4.17 (2.38 to 7.32)</td> <td align="left" rowspan="1" colspan="1" /> <td align="left" rowspan="1" colspan="1">6.22 (2.71 to 14.30)<a href="#jia225610-note-0006"><sup>c</sup></a></td> <td align="left" rowspan="1" colspan="1" /> <td align="left" rowspan="1" colspan="1" /> </tr> <tr> <td align="left" style="padding-left:10%" rowspan="1" colspan="1">SoCâ€�eligible</td> <td align="left" rowspan="1" colspan="1">402</td> <td align="left" rowspan="1" colspan="1">650.0</td> <td align="left" rowspan="1" colspan="1">0.62</td> <td align="left" rowspan="1" colspan="1">308</td> <td align="left" rowspan="1" colspan="1">813.7</td> <td align="left" rowspan="1" colspan="1">0.38</td> <td align="left" rowspan="1" colspan="1">6.51 (4.07 to 10.42)</td> <td align="left" rowspan="1" colspan="1" /> <td align="left" rowspan="1" colspan="1">9.25 (4.53 to 18.91)<a href="#jia225610-note-0011"><sup>h</sup></a></td> <td align="left" rowspan="1" colspan="1" /> <td align="left" rowspan="1" colspan="1" /> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN" id="jia225610-ntgp-0003"> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>a</sup></span><p>HR compared to standard of care rates</p> </div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>b</sup></span><p>Not adjusted for multiplicity</p> </div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>c</sup></span><p>adjusted for steptime, age at study enrolment (18 to &amp;lt;20Â years old, 20 to &amp;lt;30Â years old, 30 to &amp;lt;40Â years old, 40 to &amp;lt;50Â years old, 50 to &amp;lt;60Â years old, 60+ years old), sex, marital status (married, divorced/widowed, single), education (illiterate/primary, secondary, high school, tertiary), CD4 counts (&amp;lt;350, 350 to 500, &amp;gt;500), WHO stage (stage 1, stage 2, stage 3 or 4), BMI (&amp;lt;18.5, 18.5 to &amp;lt;25, 25 to &amp;lt;30, â‰¥30), screened for TB symptoms (yes, no), viral load (&amp;lt;5000, 5000 to 30â€š000, &amp;gt;30â€š000), treatment support (yes, no), level of clinic (Hospital, Clinic with maternity, Clinic without maternity), time from HIV tested positive to enrolment (â‰¤1Â year, 1 to â‰¤3Â years, &amp;gt;3Â years), clinic volume (Low: &amp;lt; median, High: â‰¥median</p> </div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>d</sup></span><p>same as footnote 2, plus study enrolment date (continuous)</p> </div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>e</sup></span><p>came as footnote 2, plus study enrolment date (2 knot restricted cubic splines). If CD4/WHO at 180Â days post ART initiation was not available, use CD4/WHO at ART initiation if available, or CD4/WHO at study enrolment if available. For WHO stage at 180Â days post ART initiation, which had too few missing to use the missing indicator method, the missings were assigned to the reference category.</p> </div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>f</sup></span><p>same as footnote 4</p> </div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>g</sup></span><p>same as footnote 2, plus study enrolment date (2 knots stepwise restricted cubic spline)</p> </div> <div class="fn-type-" title=""><span class="label" tagx="label" title="label"><sup>h</sup></span><p>same as footnote 2, plus study enrolment date (3 knots stepwise restricted cubic spline).</p> </div> </div> <div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">John Wiley &amp;amp; Sons, Ltd</span>, </span></div> </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 3</span></a></div>   <p>Kaplanâ€"Meier curves for retention. <b>(a)</b> all participants, <b>(b)</b> above SoC and <b>(c)</b> under SoC. Graphs reflect the cumulative incidence averaged over covariates. Full multivariable model adjusted for steptime, age (18â€�&amp;lt;20Â years old, 20â€�&amp;lt;30Â years old, 30â€�&amp;lt;40Â years old, 40â€�&amp;lt;50Â years old,5 0â€�&amp;lt;60Â year old, 60Â +Â years old), sex, marital status (Married, Divorced/Widowed, Single), education (Illiterate/Primary, Secondary, High School, Tertiary), CD4 (&amp;lt;350, 350 to 500, &amp;gt;500), WHO stage (stage 1, stage 2, stage 3 or 4), BMI (&amp;lt;18.5, 18.5â€�&amp;lt;25, 25 to &amp;lt;30, â‰¥30), screened for TB symptoms (yes, no), viral load (&amp;lt;5â€š000, 5â€š000 to 30â€š000, &amp;gt;30â€š000), access to HIV treatment supporter (yes, no), level of clinic (Hospital, Clinic with maternity, Clinic without maternity), time from HIV tested positive to enrolment (â‰¤1Â year, 1â€� â‰¤3Â years, &amp;gt;3Â years), clinic volume (Low: &amp;lt; median, High: â‰¥ median). Missing data were treated as a separate group for each of the covariates in the models. All adjusted variables were derived at study enrolment. Marginal model was used to adjust for clustering effect among facilities. SoCâ€�ineligible also included an additional variable for study enrolment date (continuous) in the model</p>   </div> <p>In addition, we carried out subgroup analyses in participants eligible for ART at the time of enrolment under the current SoC (â€œSoC eligibleâ€�), and in participants eligible only under EAAA (â€œSoC ineligibleâ€�). There was strong evidence of similar rates of improvement in retention, viral suppression at six months or more after ART initiation, and the combined endpoint for both subpopulations (TableÂ <a href="#jia225610-tbl-0003">3</a> and FigureÂ <a href="#jia225610-sup-0001">S5</a>). The estimated effect sizes and significance levels for both retention and viral suppression increased after multivariable adjustment (TableÂ <a href="#jia225610-tbl-0003">3</a>).</p> <p>In our analysis, 74% of the unsuppressed VLs were due to the lack of any measurements six months or more following ART initiation. Among those lacking measurements, 50% of those participants were missing VL due to no clinic visits during this time, with the other 50% had missing VL despite having had a least one clinical visit in this time window. In an attempt to separate out the effects of EAAA itself from the health system capacity to conduct adequate VL monitoring, we conducted several sensitivity analyses, with multivariableâ€�adjusted results as follows: 1) Including only participants with VL measured after baseline, the effect of EAAA on viral suppression and ability to provide VL measurements six months or more after ART initiation among those retained was 3.60 (95% CI: 2.13 to 6.09) times higher among those under EAAA compared to SoC. 2) Considering the most extreme scenario for those missing VLs â€" that participants enrolled under EAAA were considered unsuppressed, and participants enrolled under SoC were considered suppressed â€" we found that EAAA participants were 2.09 (95% CI: 1.26 to 3.46) times as likely to be suppressed by end of followâ€�up compared to SoC participants. 3) Considering that those with missing VLs six months or more following ART initiation were treated as suppressed at all clinic visits, assuming that even if there were no VLs recorded, participants were appropriately treated at their visits, results were substantially attenuated in this analysis: the steptimeâ€�adjusted HRs (95% CI, <i>p</i>â€�value) were 1.89 (1.13 to 3.17, 0.01) compared to 14.51 (7.31 to 28.79, &amp;lt;0.001) in the original approach. These two results can be considered an upper and lower bound on the effectiveness of EAAA on viral suppression six months post ART initiation among those retained. Since some participants attending clinic without VLs were likely unsuppressed, if all VLs were available, the findings would likely be somewhere in between these two bounds. Of course, missed clinic visits leads to nonâ€�adherence, since the provision of medications was matched to the clinic visit schedule; thus, it is reasonable to treat missing clinic visits as unsuppressed VLs. Clearly, the strong effect of EAAA on viral suppression was both a function of the EAAA itself as well as the enhanced health system capabilities. Competing risk analysis for this endpoint produced HRs materially unchanged from the primary analysis (data not shown).</p> <p>Furthermore, in sensitivity analysis for the combined endpoint, as we varied the unsuppression rate among those with missing VL from 5% to 20%, the benefit of the combined endpoint as HRs increased from 1.84 (95% CI: 1.23 to 2.77) to 2.20 (95% CI: 1.42 to 3.41), demonstrating that even with very high suppression rates among those with missing VLs, there was still an increased rate of retention and/or viral suppression associated with EAAA.</p> <p>Finally, after consideration of multiple comparisons, there were only three significant instances of effect modification on any of the three endpoints by covariates (FiguresÂ <a href="#jia225610-sup-0001">S6</a>,<a href="#jia225610-sup-0001">S7</a>,<a href="#jia225610-sup-0001">S8</a> and TablesÂ <a href="#jia225610-sup-0001">S1</a>,<a href="#jia225610-sup-0001">S2</a>,<a href="#jia225610-sup-0001">S3</a>). Viral suppression and the combined endpoint varied significantly by facility level, with EAAA having the strongest effect on these endpoints in hospitals, and the weakest in clinics with no maternity facilities. We did not assess effect modification by clinic for the viral suppression endpoint because some clinics had no participants available for assessment.</p> </div> <div class="discussion" title="discussion"><span class="label" tagx="label" title="label">4</span><div class="title" tagx="title" title="title">
Discussion</div> <p>This is the first randomized controlled trial to establish the impact of EAAA on the critical endpoints of ART retention and viral suppression in a â€œrealâ€�worldâ€� public sector health system setting in subâ€�Saharan Africa. Increased retention and viral suppression at six months or more after ART initiation was observed with EAAA compared to SoC, similar to previous observational data showing that those immediately eligible for ART had higher retention rates under existing national guidelines, than participants above the eligibility criteria [<a href="#jia225610-bib-0028">28</a>, <a href="#jia225610-bib-0029">29</a>]. EAAA led to both a 60% increase in retention rates and â€" when considering documented viral load â€" a fivefold increase in retention and viral suppression combined. VL suppression can be considered a proxy measurement of health system efficiency, simultaneously assessing retention, the ability of the healthcare system to provide a VL result, and when available, to maintain suppression. When only those with at least one VL measurement postâ€�ART are included, the 6â€� and 12â€�month suppression rates were 0.94 and 0.91 in the EAAA participants, and 0.82 and 0.72 among SoC participants (FigureÂ <a href="#jia225610-sup-0001">S3</a>). However, when we assume that those who died, were lost to followâ€�up or were likely untreated due to not having VLs measured were all unsuppressed, as in the definition given in FigureÂ <a href="#jia225610-sup-0001">S2</a>, the sixâ€� and twelveâ€�month suppression rates were 0.90 and 0.79 in the EAAA participants, and 0.22 and 0.04 among SoC participants. Most studies are likely estimating suppression rates with these antiâ€�conservative assumptions, while the estimates we provided in our primary analysis may be much closer to the reality and could explain, at least in part, why transmission is still so high in, for example, Kwa Zulu Natal, South Africa, bordering Eswatini [<a href="#jia225610-bib-0030">30</a>]. Calendar time was controlled for in all analyses, thus eliminating background time trends related to a general improvement in the quality of care as an explanation for the large observed increase in viral suppression among the EAAA group.</p> <p>Lessons learned from this trial are as follows: EAAA can be successfully implemented in a public sector health system, supporting Eswatini and other countries' decisions to roll out this policy as the SoC. EAAA adoption did not lead to a deterioration of clinical performance of the public sector ART provision, as some had feared. Selfâ€�reported adherence and disclosure levels remained high after the introduction of EAAA, and we also observed an improvement in the health care interactions, possibly due to training at participating facilities, which will be an important element for a successful rollout of immediate ART [<a href="#jia225610-bib-0031">31</a>]. Thus, EAAA not only benefited those who are either newly diagnosed or enrolled in preâ€�ART but also those who were eligible for ART prior to EAAA. EAAA may be a particularly useful policy for providing ART coverage to all people living with HIV while supporting the attainment of the UNAIDS 90â€�90â€�90 target. Even in this resourceâ€�limited, public sector clinical setting, EAAA participants were initiated on ART 3.6 fold faster than SoC participants (<i>p</i>Â <div class="â_UNKNOWN" href="#jia225610-bib-0032">
32, <a href="#jia225610-bib-0033">33</a>, <a href="#jia225610-bib-0034">34</a>, <a href="#jia225610-bib-0035">35</a>].</div></p> <p>This trial had several limitations. The Eswatini national ART guidelines evolved during the trial from recommending ART initiation at CD4Â â‰¤Â 350 to CD4Â â‰¤Â 500 and finally to EAAA. These changes over time reduced the statistical power to demonstrate significant impact of EAAA compared with the SoC. However, because the effect sizes were of a greater magnitude than anticipated, we were nevertheless able to observe highly significant EAAA effects.</p> <p>Another limitation of this trial resulted from a relatively high proportion of missing VL measurements. In the primary analysis, we treated all missing VLs as detectable. If VLs are not measured as per national guidelines, it is difficult to properly treat participants, correct treatment failure and monitor and address nonâ€�adherence. Insufficient VL monitoring is equivalent to being unsuppressed from health systems, patient safety and disease transmission standpoints. Under the national guidelines, VLs are not measured until ART initiation and every six months thereafter. Thus, even if SoC and EAAA were compared contemporaneously, there would be more VLs in the EAAA group since EAAA participants are immediately initiated regardless of clinical status. However, the sensitivity analyses demonstrated that regardless of whether we included only those with at least one VL measurement after baseline, considered all EAAA participants without VLs as unsuppressed and SoC participants without VLs as suppressed, or considered all participants with missing VLs suppressed, results gave similarly attenuated but nevertheless significant improvements in suppression rates.</p> <p>These realâ€�world limitations highlight the significant implementation challenges for the scaleâ€�up of VL testing. The relatively poor performance in ensuring regular and timely VL testing is in line with results from public sector ART programmes in six other subâ€�Saharan African countries [<a href="#jia225610-bib-0036">36</a>]. Anecdotally reported reasons for the relatively poor VL testing performance included unavailability of daily sample transport, improper timing of sample pickups and a lack of centrifuge and plasma storage capabilities. Our trial was conducted under â€œreal lifeâ€� conditions. In contrast, at least two of the trials testing the effect of EAAA on HIV incidence have been carried out in a researchâ€�grade clinical trial setting supported by dedicated trial staff. In these trials, VL testing occurred with adherence to recommended schedules that exceeded the level achieved in publicâ€�sector provision in â€œreal lifeâ€� [<a href="#jia225610-bib-0003">3</a>, <a href="#jia225610-bib-0037">37</a>]. The results from these studies could thus be considered closer to the efficacy end of the EAAA effect size spectrum, while our results could be considered closer to the effectiveness end of the spectrum.</p> </div> <div class="conclusions" title="conclusions"><span class="label" tagx="label" title="label">5</span><div class="title" tagx="title" title="title">
Conclusions</div> <p>Our findings provide strong causal evidence for the benefits of EAAA on retention and viral suppression, both for those who were already eligible for ART under the previous eligibility thresholds and for those who became newly eligible under EAAA. Thus, Eswatini and other countries with similar HIV epidemics and health systems should continue their rollout of EAAA. EAAA policies will likely not only improve access to ART but also the clinical performance of ART programmes with respect to patient outcomes.</p> </div> <div class="competinginterests" title="sec"> <div class="title" tagx="title" title="title">
Competing Interests</div> <p>All authors declare no competing interests.</p> </div> <div class="authorsâ€™contributions" title="sec"> <div class="title" tagx="title" title="title">
Authorsâ€™ Contributions</div> <p>TB, VO, DS and FW (alphabetical order) designed the trial. AH, CL, SK, KM, EM, SM and MP (alphabetical order) implemented the trial. TB, AC, SK, DS and FW searched the literature and wrote the manuscript. AC, BC and DS (alphabetical order) conducted the statistical analysis and sample size calculations. TB, AC, WD, YF, AH, CL, GK, SK, KM, SM, VO, MP, RR, DS, FW and MZ (alphabetical order) contributed to the interpretation and presentation of the findings. All authors contributed to and approved the final version of the manuscript for submission.</p> </div> <div class="datasafetymonitoringboard" title="sec"> <div class="title" tagx="title" title="title">
Data Safety Monitoring Board</div> <p>Sten Vermund, USA (chair); Nhlanhla Nhlabatsi, Eswatini (coâ€�chair); Rhinos Chekenyere, Eswatini; Shaffiq Essajee, USA; Nomsa Mulima, Eswatini; and Candida Moshiro, Tanzania.</p> </div> <div class="supplementary-material" title="supplementary-material"> <div class="title" tagx="title" title="title">
Supporting information</div> <div class="local-data" title="local-data">  <p><b>Figure S1.</b> Definition of nonâ€�retention.</p> <p><b>Figure S2.</b> Definition of viral suppression.</p> <p><b>Figure S3.</b> Kaplanâ€�Meier curves for viral suppression. (a) all participants, (b) SoC ineligible and (c) SoC eligible.</p> <p><b>Figure S4.</b> Kaplanâ€�Meier curves for combined endpoint, retention and viral suppression. (a) all participants, (b) above SoC and (c) under SoC participants.</p> <p><b>Figure S5.</b> Forest plot of the intervention effect modification for retention, by covariates.</p> <p><b>Figure S6.</b> Forest plot of the intervention effect modification for retention, by covariates.</p> <p><b>Figure S7.</b> Forest plot of the intervention effect modification for viral suppression, by covariates.</p> <p><b>Figure S8.</b> Forest plot of the intervention effect modification for the combined endpoint, by covariates</p> <p><b>Talbe S1.</b> Effect of EAAA on retention among all participants, by preâ€�specified subgroups.</p> <p><b>Table S2.</b> Effect of EAAA on viral suppression six months or more after ART initiation among all participants retained to ART initiation, by preâ€�specified subgroups</p> <p><b>Table S3.</b> Effect of EAAA on retention and viral suppression among all participants, by preâ€�specified subgroups</p>  <div class="media" title="media"><a href="JIA2-23-e25610-s001.docx">LINK</a> <p>Click here for additional data file.</p>  </div> </div> </div> </div> <div class="back" title="back"> <div class="ack" title="ack"> <div class="title" tagx="title" title="title">
Acknowledgements</div> <p>The members of the MaxART Consortium included the Eswatini Ministry of Health, Aidsfonds, Clinton Health Access Initiative (CHAI), the Eswatini National Network of People Living with HIV/AIDS (SWANNEPHA), the Southern African AIDS Information Dissemination Service (SAfAIDS), the South African Centre for Epidemiological Modelling and Analysis (SACEMA) and University of Amsterdam (UvA).</p> <div class="funding" title="sec"> <div class="title" tagx="title" title="title">
Funding</div> <p>This trial was funded by the Dutch Postcode Lottery in the Netherlands, and the Embassy of the Kingdom of the Netherlands in Mozambique, and supported by Mylan Laboratories Limited, which provided the antiretroviral drugs; MÃ©decins Sans FrontiÃ¨res (with funding from UNITAID) for VL testing; and British Columbia Centre for Excellence in HIV/AIDS for genotype testing. The MaxART Consortium thanks the many health workers and community members who actively participated in the MaxART study implementation. TB was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the Federal Ministry of Education and Research; the Wellcome Trust; the European Commission; the Clinton Health Access Initiative; and from NICHD of NIH (R01â€�HD084233), NIA of NIH (P01â€�AG041710), NIAID of NIH (R01â€�AI124389 and R01â€�AI112339) as well as FIC of NIH (D43â€�TW009775). DS was supported, in part, by NIH R01AI112339.</p> </div> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="jia225610-bib-0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: UNAIDS</span> . <span class="mixed-article-title" title="mixed-article-title">UNAIDS 2019 Data. Jt. United Nations Program</span>. HIV/AIDS. <span class="year" tagx="year" title="year">2019</span>.</span></li> <li tag="ref"><a name="jia225610-bib-0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cohen</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">YQ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">McCauley</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gamble</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hosseinipour</span><span class="given-names" tagx="given-names" title="given-names">MC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kumarasamy</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Prevention of HIVâ€�1 infection with early antiretroviral therapy</span>. <span class="source" tagx="source" title="source">N Engl J Med</span>. <span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">375</span>(<span class="issue" tagx="issue" title="issue">9</span>):<span class="fpage" tagx="fpage" title="fpage">830</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.</span></li> <li tag="ref"><a name="jia225610-bib-0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Iwuji</span><span class="given-names" tagx="given-names" title="given-names">CC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Orneâ€�Gliemann</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Larmarange</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Balestre</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Thiebaut</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Tanser</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, openâ€�label, community cluster randomised trial</span>. <span class="source" tagx="source" title="source">Lancet HIV</span>. <span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">5</span>(<span class="issue" tagx="issue" title="issue">3</span>):e116â€"25.</span></li> <li tag="ref"><a name="jia225610-bib-0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Makhema</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wirth</span><span class="given-names" tagx="given-names" title="given-names">KE</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Holme</span><span class="given-names" tagx="given-names" title="given-names">MP</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gaolathe</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mmalane</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kadima</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Universal testing, expanded treatment, and incidence of HIV infection in Botswana</span>. <span class="source" tagx="source" title="source">N Engl J Med</span>. <span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">381</span>(<span class="issue" tagx="issue" title="issue">3</span>):<span class="fpage" tagx="fpage" title="fpage">230</span>â€"<span class="lpage" tagx="lpage" title="lpage">42</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31314967">31314967</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hayes</span><span class="given-names" tagx="given-names" title="given-names">RJ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Donnell</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Floyd</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mandla</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bwalya</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Sabapathy</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Effect of universal testing and treatment on HIV incidence â€� HPTN 071 (PopArt)</span>. <span class="source" tagx="source" title="source">N Engl J Med</span>. <span class="volume" tagx="volume" title="volume">381</span>(<span class="issue" tagx="issue" title="issue">3</span>):<span class="fpage" tagx="fpage" title="fpage">207</span>â€"<span class="lpage" tagx="lpage" title="lpage">18</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31314965">31314965</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Havlir</span><span class="given-names" tagx="given-names" title="given-names">DV</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Balzer</span><span class="given-names" tagx="given-names" title="given-names">LB</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Charlebois</span><span class="given-names" tagx="given-names" title="given-names">ED</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Clark</span><span class="given-names" tagx="given-names" title="given-names">TD</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kwarisiima</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ayieko</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">HIV testing and treatment with the use of a community health approach in rural Africa</span>. <span class="source" tagx="source" title="source">N Engl J Med</span>. <span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">381</span>(<span class="issue" tagx="issue" title="issue">3</span>):<span class="fpage" tagx="fpage" title="fpage">219</span>â€"<span class="lpage" tagx="lpage" title="lpage">29</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31314966">31314966</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Larmarange</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Diallo</span><span class="given-names" tagx="given-names" title="given-names">MH</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">McGrath</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Iwuji</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Plazy</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">ThiÃ©baut</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa</span>. <span class="source" tagx="source" title="source">J Int AIDS Soc</span>. <span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">22</span>:<span class="elocation-id" tagx="elocation-id" title="elocation-id">e25402</span><span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31637821">31637821</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Tanser</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">Hâ€�Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Vandormael</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Iwuji</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">BÃ¤rnighausen</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>. <span class="mixed-article-title" title="mixed-article-title">Opportunities and challenges in HIV treatment as prevention research: results from the ANRS 12249 clusterâ€�randomized trial and associated population cohort</span>. <span class="source" tagx="source" title="source">Curr HIV/AIDS Rep</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">17</span>:<span class="fpage" tagx="fpage" title="fpage">97</span>â€"<span class="lpage" tagx="lpage" title="lpage">108</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/32072468">32072468</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: Kingdom of Eswatini</span> . <span class="mixed-article-title" title="mixed-article-title">Preliminary findings â€� Swaziland HIV incidence measurement survey 2: a populationâ€�based HIV impact assessment (SHIMS2 2016â€"207)</span>. <span class="year" tagx="year" title="year">2017</span>.</span></li> <li tag="ref"><a name="jia225610-bib-0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: World Health Organization</span> . <span class="source" tagx="source" title="source">Guideline on when to start antiretroviral therapy and on preâ€�exposure prophylaxis for HIV</span>. <span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">Geneva</span>: <span class="publisher-name" tagx="publisher-name" title="publisher-name">World Health Organization</span>; <span class="year" tagx="year" title="year">2015</span>. .</span></li> <li tag="ref"><a name="jia225610-bib-0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Walsh</span><span class="given-names" tagx="given-names" title="given-names">FJ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">BÃ¤rnighausen</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Delva</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Fleming</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Khumalo</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lejeune</span><span class="given-names" tagx="given-names" title="given-names">CL</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Impact of early initiation versus national standard of care of antiretroviral therapy in Swazilandâ€™s public sector health system: Study protocol for a steppedâ€�wedge randomized trial</span>. <span class="source" tagx="source" title="source">Trials</span>. <span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">18</span>:<span class="fpage" tagx="fpage" title="fpage">383</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28821264">28821264</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Giordano</span><span class="given-names" tagx="given-names" title="given-names">TP</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gifford</span><span class="given-names" tagx="given-names" title="given-names">AL</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">White</span><span class="given-names" tagx="given-names" title="given-names">AC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Almazor</span><span class="given-names" tagx="given-names" title="given-names">MES</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rabeneck</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hartman</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Retention in care: a challenge to survival with HIV infection</span>. <span class="source" tagx="source" title="source">Clin Infect Dis</span>. <span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">44</span>(<span class="issue" tagx="issue" title="issue">11</span>):<span class="fpage" tagx="fpage" title="fpage">1493</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17479948">17479948</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Grinsztejn</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Hosseinipour</span><span class="given-names" tagx="given-names" title="given-names">MC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ribaudo</span><span class="given-names" tagx="given-names" title="given-names">HJ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Swindells</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Eron</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chen</span><span class="given-names" tagx="given-names" title="given-names">YQ</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIVâ€�1 infection: results from the phase 3 HPTN 052 randomised controlled trial</span>. <span class="source" tagx="source" title="source">Lancet Infect Dis</span>. <span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">14</span>:<span class="fpage" tagx="fpage" title="fpage">281</span>â€"<span class="lpage" tagx="lpage" title="lpage">90</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24602844">24602844</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ogbuoji</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Geldsetzer</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wong</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mafara</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lejeune</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Impact of immediate initiation of antiretroviral therapy on HIV patient satisfaction</span>. <span class="source" tagx="source" title="source">AIDS</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">34</span>(<span class="issue" tagx="issue" title="issue">2</span>):<span class="fpage" tagx="fpage" title="fpage">267</span>â€"<span class="lpage" tagx="lpage" title="lpage">76</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31634194">31634194</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Molemans</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Vernooij</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Dlamini</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shabalala</span><span class="given-names" tagx="given-names" title="given-names">FS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">van Leth</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Changes in disclosure, adherence and healthcare interactions after the introduction of immediate ART initiation: an analysis of patient experiences in Swaziland</span>. <span class="source" tagx="source" title="source">Trop Med Int Heal</span>. <span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">24</span>(<span class="issue" tagx="issue" title="issue">5</span>):<span class="fpage" tagx="fpage" title="fpage">563</span>â€"<span class="lpage" tagx="lpage" title="lpage">70</span>.</span></li> <li tag="ref"><a name="jia225610-bib-0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chao</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Spiegelman</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Walsh</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mazibuko</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Pasipamire</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Mortality under early access to antiretroviral therapy vs. eswatiniâ€™s national standard of care: the MaxART clustered randomized steppedâ€�wedge trial</span>. <span class="source" tagx="source" title="source">HIV Med. Forthcoming</span>. <span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">21</span>(<span class="issue" tagx="issue" title="issue">7</span>):<span class="fpage" tagx="fpage" title="fpage">429</span>â€"<span class="lpage" tagx="lpage" title="lpage">40</span>.</span></li> <li tag="ref"><a name="jia225610-bib-0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cox</span><span class="given-names" tagx="given-names" title="given-names">DR</span></span>. <span class="mixed-article-title" title="mixed-article-title">Regression models and lifeâ€�tables</span>. <span class="source" tagx="source" title="source">J R Stat Soc Ser B</span>. <span class="year" tagx="year" title="year">1972</span>;<span class="volume" tagx="volume" title="volume">34</span>(<span class="issue" tagx="issue" title="issue">2</span>):<span class="fpage" tagx="fpage" title="fpage">187</span>â€"<span class="lpage" tagx="lpage" title="lpage">202</span>.</span></li> <li tag="ref"><a name="jia225610-bib-0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">DY</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wei</span><span class="given-names" tagx="given-names" title="given-names">LJ</span></span>. <span class="mixed-article-title" title="mixed-article-title">The robust inference for the cox proportional hazards model</span>. <span class="source" tagx="source" title="source">J Am Stat Assoc</span>. <span class="year" tagx="year" title="year">1989</span>;<span class="volume" tagx="volume" title="volume">84</span>(<span class="issue" tagx="issue" title="issue">408</span>):<span class="fpage" tagx="fpage" title="fpage">1074</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.</span></li> <li tag="ref"><a name="jia225610-bib-0019" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cook</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>.<span class="mixed-article-title" title="mixed-article-title">Smallâ€�sample robust variance correction for generalized estimating equations for use in cluster randomized clinical trials</span>. NIH Collaboratory. <span class="year" tagx="year" title="year">2015</span> Available from: <a href="https://www.nihcollaboratory.org/Products/Variance-correction-for-GEE_V1">https://www.nihcollaboratory.org/Products/Varianceâ€�correctionâ€�forâ€�GEE_V1</a> (accessed 2020 Apr 27).</span></li> <li tag="ref"><a name="jia225610-bib-0020" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Maldonado</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Greenland</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>. <span class="mixed-article-title" title="mixed-article-title">Simulation Study Of Confounderâ€�Selection Strategies</span>. <span class="source" tagx="source" title="source">Am J Epidemiol</span>. <span class="year" tagx="year" title="year">1993</span>;<span class="volume" tagx="volume" title="volume">138</span>(<span class="issue" tagx="issue" title="issue">11</span>):<span class="fpage" tagx="fpage" title="fpage">923</span>â€"<span class="lpage" tagx="lpage" title="lpage">36</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/8256780">8256780</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0021" /><span class="label" tagx="label" title="label">21</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Govindarajulu</span><span class="given-names" tagx="given-names" title="given-names">US</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Spiegelman</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Thurston</span><span class="given-names" tagx="given-names" title="given-names">SW</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ganguli</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Eisen</span><span class="given-names" tagx="given-names" title="given-names">EA</span></span>. <span class="mixed-article-title" title="mixed-article-title">Comparing smoothing techniques in Cox models for exposureâ€�response relationships</span>. <span class="source" tagx="source" title="source">Stat Med</span>. <span class="year" tagx="year" title="year">2007</span>;<span class="volume" tagx="volume" title="volume">26</span>(<span class="issue" tagx="issue" title="issue">20</span>):<span class="fpage" tagx="fpage" title="fpage">3735</span>â€"<span class="lpage" tagx="lpage" title="lpage">52</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/17538974">17538974</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0022" /><span class="label" tagx="label" title="label">22</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Miettinen</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>. <span class="source" tagx="source" title="source">Theoretical epidemiology: principles of occurrence research in medicine</span>, <span class="edition" tagx="edition" title="edition">1st edn</span><span class="publisher-loc" tagx="publisher-loc" title="publisher-loc">New York, NY</span>: <span class="publisher-name" tagx="publisher-name" title="publisher-name">John Wiley &amp;amp; Sons</span>; <span class="year" tagx="year" title="year">1985</span>.</span></li> <li tag="ref"><a name="jia225610-bib-0023" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Fine</span><span class="given-names" tagx="given-names" title="given-names">JP</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Gray</span><span class="given-names" tagx="given-names" title="given-names">RJ</span></span>. <span class="mixed-article-title" title="mixed-article-title">A proportional hazards model for the subdistribution of a competing risk</span>. <span class="source" tagx="source" title="source">J Am Stat Assoc</span>. <span class="year" tagx="year" title="year">1999</span>;<span class="volume" tagx="volume" title="volume">94</span>(<span class="issue" tagx="issue" title="issue">446</span>):<span class="fpage" tagx="fpage" title="fpage">496</span>â€"<span class="lpage" tagx="lpage" title="lpage">509</span>.</span></li> <li tag="ref"><a name="jia225610-bib-0024" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rothman</span><span class="given-names" tagx="given-names" title="given-names">KJ</span></span>. <span class="mixed-article-title" title="mixed-article-title">No adjustments are needed for multiple comparisons</span>. <span class="source" tagx="source" title="source">Epidemiology</span>. <span class="year" tagx="year" title="year">1990</span>;<span class="volume" tagx="volume" title="volume">1</span>(<span class="issue" tagx="issue" title="issue">1</span>):<span class="fpage" tagx="fpage" title="fpage">43</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2081237">2081237</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0025" /><span class="label" tagx="label" title="label">25</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="collab'">collab: ICAP and the Swaziland Ministry of Health</span> . <span class="mixed-article-title" title="mixed-article-title">PHIA Project. Swaziland HIV incidence measurement survey 2: a Populationâ€�based HIV impact assessment SHIMS2 2016â€"2017</span>.</span></li> <li tag="ref"><a name="jia225610-bib-0026" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Haber</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Pillay</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Porter</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Barnighausen</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>. <span class="mixed-article-title" title="mixed-article-title">Constructing the cascade of HIV care: methods for measurement</span>. <span class="source" tagx="source" title="source">Curr Opin HIV AIDS</span>. <span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">11</span>(<span class="issue" tagx="issue" title="issue">1</span>):<span class="fpage" tagx="fpage" title="fpage">102</span>â€"<span class="lpage" tagx="lpage" title="lpage">108</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26545266">26545266</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0027" /><span class="label" tagx="label" title="label">27</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Haber</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Tanser</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bor</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Naidu</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mutevedzi</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Herbst</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">From HIV infection to therapeutic response: a populationâ€�based longitudinal HIV cascadeâ€�ofâ€�care study in KwaZuluâ€�Natalm, South Africa</span>. <span class="source" tagx="source" title="source">Lancet HIV</span>. <span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">4</span>(<span class="issue" tagx="issue" title="issue">5</span>):e223â€"30.</span></li> <li tag="ref"><a name="jia225610-bib-0028" /><span class="label" tagx="label" title="label">28</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Bor</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Fox</span><span class="given-names" tagx="given-names" title="given-names">MP</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Rosen</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Venkataramani</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Tanser</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Pillay</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Treatment eligibility and retention in clinical HIV care: a regression discontinuity study in South Africa</span>. <span class="source" tagx="source" title="source">PLoS Medicine</span>. <span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">14</span>:<span class="elocation-id" tagx="elocation-id" title="elocation-id">e1002463</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29182641">29182641</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0029" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lessells</span><span class="given-names" tagx="given-names" title="given-names">RJ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mutevedzi</span><span class="given-names" tagx="given-names" title="given-names">PC</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Cooke</span><span class="given-names" tagx="given-names" title="given-names">GS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Newell</span><span class="given-names" tagx="given-names" title="given-names">ML</span></span>. <span class="mixed-article-title" title="mixed-article-title">Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZuluâ€�Natal, South Africa</span>. <span class="source" tagx="source" title="source">J Acquir Immune Defic Syndr</span>. <span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">56</span>(<span class="issue" tagx="issue" title="issue">3</span>):e79â€"86.</span></li> <li tag="ref"><a name="jia225610-bib-0030" /><span class="label" tagx="label" title="label">30</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ramjee</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Sartorius</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Morris</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Wand</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Reddy</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Yssel</span><span class="given-names" tagx="given-names" title="given-names">JD</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">A decade of sustained geographic spread of HIV infections among women in Durban, South Africa</span>. <span class="source" tagx="source" title="source">BMC Infect Dis</span>. <span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">19</span>(<span class="issue" tagx="issue" title="issue">1</span>):<span class="fpage" tagx="fpage" title="fpage">500</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31174475">31174475</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0031" /><span class="label" tagx="label" title="label">31</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Molemans</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Vernooij</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Dlamini</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Shabalala</span><span class="given-names" tagx="given-names" title="given-names">FS</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Khan</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">van Leth</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Changes in disclosure, adherence and healthcare interactions after the introduction of immediate ART initiation: an analysis of patient experiences in Swaziland</span>. <span class="source" tagx="source" title="source">Trop Med Int Health</span>. <span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">24</span>(<span class="issue" tagx="issue" title="issue">5</span>):<span class="fpage" tagx="fpage" title="fpage">563</span>â€"<span class="lpage" tagx="lpage" title="lpage">70</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30739385">30739385</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0032" /><span class="label" tagx="label" title="label">32</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Barnighausen</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chaiyachati</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chimbindi</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Peoples</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Haberer</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Newell</span><span class="given-names" tagx="given-names" title="given-names">ML</span></span>. <span class="mixed-article-title" title="mixed-article-title">Interventions to increase antiretroviral adherence in subâ€�Saharan Africa: a systematic review of evaluation studies</span>. <span class="source" tagx="source" title="source">Lancet Infect Dis</span>. <span class="year" tagx="year" title="year">2011</span>;<span class="volume" tagx="volume" title="volume">11</span>(<span class="issue" tagx="issue" title="issue">12</span>):<span class="fpage" tagx="fpage" title="fpage">942</span>â€"<span class="lpage" tagx="lpage" title="lpage">51</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22030332">22030332</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0033" /><span class="label" tagx="label" title="label">33</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Barnighausen</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Tanser</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Dabis</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Newell</span><span class="given-names" tagx="given-names" title="given-names">ML</span></span>. <span class="mixed-article-title" title="mixed-article-title">Interventions to improve the performance of HIV health systems for treatmentâ€�asâ€�prevention in subâ€�Saharan Africa: the experimental evidence</span>. <span class="source" tagx="source" title="source">Curr Opin HIV AIDS</span>. <span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">7</span>(<span class="issue" tagx="issue" title="issue">2</span>):<span class="fpage" tagx="fpage" title="fpage">140</span>â€"<span class="lpage" tagx="lpage" title="lpage">50</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/22248917">22248917</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0034" /><span class="label" tagx="label" title="label">34</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Mills</span><span class="given-names" tagx="given-names" title="given-names">EJ</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lester</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Thorlund</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lorenzi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Muldoon</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kanters</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Interventions to promote adherence to antiretroviral therapy in Africa: a network metaâ€�analysis</span>. <span class="source" tagx="source" title="source">Lancet HIV</span>. <span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">1</span>(<span class="issue" tagx="issue" title="issue">3</span>):e104â€"111.</span></li> <li tag="ref"><a name="jia225610-bib-0035" /><span class="label" tagx="label" title="label">35</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chaiyachati</span><span class="given-names" tagx="given-names" title="given-names">KH</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ogbuoji</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Price</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Suthar</span><span class="given-names" tagx="given-names" title="given-names">AB</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Negussie</span><span class="given-names" tagx="given-names" title="given-names">EK</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Barnighausen</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>. <span class="mixed-article-title" title="mixed-article-title">Interventions to improve adherence to antiretroviral therapy: a rapid systematic review</span>. <span class="source" tagx="source" title="source">AIDS</span>. <span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">28</span><span class="issue" tagx="issue" title="issue">Suppl 2</span>:<span class="fpage" tagx="fpage" title="fpage">S187</span>â€"<span class="lpage" tagx="lpage" title="lpage">204</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24849479">24849479</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0036" /><span class="label" tagx="label" title="label">36</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Lecher</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Williams</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Fonjungo</span><span class="given-names" tagx="given-names" title="given-names">PN</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">AA</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ellenberger</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Zhang</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Progress with Scaleâ€�Up of HIV Viral Load Monitoring â€� Seven Subâ€�Saharan African Countries, January 2015â€�June 2016</span>. <span class="source" tagx="source" title="source">MMWR Morb Mortal Wkly Rep</span>. <span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">65</span>(<span class="issue" tagx="issue" title="issue">47</span>):<span class="fpage" tagx="fpage" title="fpage">1332</span>â€"<span class="lpage" tagx="lpage" title="lpage">5</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27906910">27906910</a></span></span></li> <li tag="ref"><a name="jia225610-bib-0037" /><span class="label" tagx="label" title="label">37</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Petersen</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Balzer</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Kwarsiima</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Sang</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Chamie</span><span class="given-names" tagx="given-names" title="given-names">G</span></span>, <span class="string-name" title="string-name"><span class="surname" tagx="surname" title="surname">Ayieko</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, et al. <span class="mixed-article-title" title="mixed-article-title">Association of implementation of a universal testing and treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral suppression in East Africa</span>. <span class="source" tagx="source" title="source">JAMA</span>. <span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">317</span>(<span class="issue" tagx="issue" title="issue">21</span>):<span class="fpage" tagx="fpage" title="fpage">2196</span>â€"<span class="lpage" tagx="lpage" title="lpage">206</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28586888">28586888</a></span></span></li> </ul> </div> </div>  </body></html>